4D Brain-Targeting Nanomedicines for Treating Neurodegeneration
This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.
Projectdetails
Introduction
Aging, genetic, and environmental factors have increased the prevalence of patients with neurodegenerative brain conditions, with limited treatment modalities. One prerequisite for effective brain treatments is the ability to target next-generation medications, including RNA and protein drugs, to specific neurons and brain regions.
Nanotechnology Platforms
Nanotechnology platforms offer new therapeutic avenues for targeting drugs to organs and cells; their implementation in neurodegenerative diseases is nascent. In this research program, we aim to advance far beyond the state-of-the-art and elucidate the molecular and structural characteristics for designing nanotechnology drugs that target and treat brain neurodegeneration.
Preliminary Studies
In preliminary studies, we show that the blood-brain barrier (BBB) overexpresses disease-specific receptors during neurodegeneration, which enable targeted nanoparticles to cross the BBB and penetrate neurons. Albeit these findings, the magnitude, mechanism, and nanotechnological molecular pattern for brain targeting are lacking.
Research Objectives
To address this fundamental gap, we will use advanced computation and engineering concepts to develop 4D-brain-targeting nanoparticles that cross the BBB intact to target specific neuronal populations and brain regions.
- Robotic Synthesis: Robotic synthesis, coupled with active learning algorithms, will be used to construct nanoparticles with combinations of targeting moieties on their surface and evaluate their neuronal specificity.
- Microfluidic Screening: Supported microfluidic BBB apparatus will be used to screen the nanoparticles’ ability to target and cross the BBB.
- Tracking System: A track-and-seek radar system will locate the nanoparticles in the brain, directing localized robotic biopsy of the nanoparticles in the destination cells in the brain.
Future Clinical Implementation
To connect our findings to future clinical implementation, fMRI will be used to record the therapeutic activity of the nanoparticles in the brain. This program will provide the community with essential findings to allow brain-targeted therapeutics.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.000.000 |
Totale projectbegroting | € 2.000.000 |
Tijdlijn
Startdatum | 1-5-2023 |
Einddatum | 30-4-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Creating an orthogonal gate to the brainThis project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer. | ERC Starting... | € 1.499.136 | 2023 | Details |
Drug DELIvery to the brain via CHOroid Plexus targetingThis project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders. | ERC Consolid... | € 1.999.756 | 2024 | Details |
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders. | ERC Proof of... | € 150.000 | 2022 | Details |
Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncologyNanoNeuroOmics aims to discover early blood biomarkers for Alzheimer's and Glioblastoma using nanotechnology and proteomics to bridge the gap between brain and blood molecular changes. | ERC Starting... | € 1.494.954 | 2025 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
Creating an orthogonal gate to the brain
This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.
Drug DELIvery to the brain via CHOroid Plexus targeting
This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.
POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders.
Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncology
NanoNeuroOmics aims to discover early blood biomarkers for Alzheimer's and Glioblastoma using nanotechnology and proteomics to bridge the gap between brain and blood molecular changes.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Distributed and federated cross-modality actuation through advanced nanomaterials and neuromorphic learningCROSSBRAIN aims to revolutionize brain condition treatment using implantable microbots for real-time, adaptive neuromodulation and sensing in rodent models of Parkinson's Disease and Epilepsy. | EIC Pathfinder | € 4.034.074 | 2022 | Details |
Wireless deep BRAIN STimulation thrOugh engineeRed Multifunctinal nanomaterialsBRAINSTORM aims to develop a scalable wireless neuromodulation technology using smart magnetic nanomaterials to selectively control deep brain neurons for therapeutic applications in Fragile X syndrome. | EIC Pathfinder | € 3.083.850 | 2023 | Details |
Minimally-Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Delivery for Neurological DisordersSoftReach aims to revolutionize neurological disorder treatments through a novel soft-growing robotic platform for localized therapeutic delivery using real-time MRI guidance. | EIC Pathfinder | € 2.158.000 | 2023 | Details |
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATIONREGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration. | EIC Pathfinder | € 2.943.233 | 2024 | Details |
4-Deep Brain ReconstructionThe 4-DBR consortium aims to develop a transplantable 4D reconstructed brain to regenerate neurological disorders, integrating advanced bioprinting and stimulation technologies for effective therapy. | EIC Pathfinder | € 2.987.775 | 2022 | Details |
Distributed and federated cross-modality actuation through advanced nanomaterials and neuromorphic learning
CROSSBRAIN aims to revolutionize brain condition treatment using implantable microbots for real-time, adaptive neuromodulation and sensing in rodent models of Parkinson's Disease and Epilepsy.
Wireless deep BRAIN STimulation thrOugh engineeRed Multifunctinal nanomaterials
BRAINSTORM aims to develop a scalable wireless neuromodulation technology using smart magnetic nanomaterials to selectively control deep brain neurons for therapeutic applications in Fragile X syndrome.
Minimally-Invasive Soft-Robot-Assisted Deep-Brain Localized Therapeutics Delivery for Neurological Disorders
SoftReach aims to revolutionize neurological disorder treatments through a novel soft-growing robotic platform for localized therapeutic delivery using real-time MRI guidance.
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.
4-Deep Brain Reconstruction
The 4-DBR consortium aims to develop a transplantable 4D reconstructed brain to regenerate neurological disorders, integrating advanced bioprinting and stimulation technologies for effective therapy.